

Cheryl L-L Chiang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2607159/publications.pdf>

Version: 2024-02-01

28
papers

1,910
citations

471509

17
h-index

677142

22
g-index

29
all docs

29
docs citations

29
times ranked

2646
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	326
2	Hypochlorous Acid: A Natural Adjuvant That Facilitates Antigen Processing, Cross-Priming, and the Induction of Adaptive Immunity. <i>Journal of Immunology</i> , 2010, 184, 824-835.	0.8	281
3	Whole Tumor Antigen Vaccines: Where Are We?. <i>Vaccines</i> , 2015, 3, 344-372.	4.4	203
4	Whole tumor antigen vaccines. <i>Seminars in Immunology</i> , 2010, 22, 132-143.	5.6	201
5	A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside. <i>Clinical Cancer Research</i> , 2013, 19, 4801-4815.	7.0	178
6	Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. <i>Oncoimmunology</i> , 2013, 2, e22664.	4.6	154
7	Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines. <i>International Reviews of Immunology</i> , 2011, 30, 150-182.	3.3	91
8	Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 1384-1395.	4.2	58
9	A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 149.	4.4	57
10	Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor. <i>Clinical Cancer Research</i> , 2008, 14, 4898-4907.	7.0	56
11	Cryoablation and Immunotherapy: An Enthralling Synergy to Confront the Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 2283.	4.8	56
12	Day-4 Myeloid Dendritic Cells Pulsed with Whole Tumor Lysate Are Highly Immunogenic and Elicit Potent Anti-Tumor Responses. <i>PLoS ONE</i> , 2011, 6, e28732.	2.5	43
13	Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. <i>Journal of Translational Medicine</i> , 2011, 9, 198.	4.4	43
14	In vivo cancer vaccination: Which dendritic cells to target and how?. <i>Cancer Treatment Reviews</i> , 2018, 71, 88-101.	7.7	32
15	Potential approaches for more successful dendritic cell-based immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 569-582.	3.1	30
16	Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer. <i>Npj Vaccines</i> , 2021, 6, 36.	6.0	27
17	The current clinical landscape of personalized cancer vaccines. <i>Cancer Treatment Reviews</i> , 2022, 106, 102383.	7.7	25
18	Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes. , 2020, 8, e000875.		16

#	ARTICLE	IF	CITATIONS
19	Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?. Current Opinion in Biotechnology, 2020, 65, 190-196.	6.6	9
20	Rate of Freeze Impacts the Survival and Immune Responses Post Cryoablation of Melanoma. Frontiers in Immunology, 2021, 12, 695150.	4.8	8
21	Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?. Vaccines, 2018, 6, 79.	4.4	7
22	Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human. Cancers, 2021, 13, 4553.	3.7	6
23	Abstract LB-335: Autologous whole-tumor antigen vaccination in combination with adoptive T cell therapy for patients with recurrent ovarian cancer.. , 2013, , .		2
24	A phase-I trial of a novel autologous oxidized whole-tumor antigen vaccine therapy for recurrent ovarian cancer. Gynecologic Oncology, 2013, 130, e11-e12.	1.4	0
25	Abstract LB-133: Vaccination with dendritic cells pulsed with autologous oxidized whole tumor lysate induced strong and long-lasting anti-tumor immunity in recurrent ovarian cancer patients. , 2012, , .		0
26	Abstract PR15: Autologous whole-tumor antigen combinatorial immunotherapy for recurrent ovarian cancer.. , 2013, , .		0
27	Abstract IA27: Combinatorial immunotherapy using whole tumor antigen: Evidence from phase I trials. , 2013, , .		0
28	Tumor lysates cancer vaccine. , 2022, , 21-49.		0